Trials / Recruiting
RecruitingNCT07377487
TheraSphere Japan Pre-Market Study
A Prospective Single-arm Study of BSJ019T in Japanese Patients With Unresectable Hepatic Malignancy Who Have Failed or Are Not Eligible for Standard Treatment
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TheraSphere Y-90 glass microsphere | TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure. |
Timeline
- Start date
- 2026-01-22
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
- First posted
- 2026-01-30
- Last updated
- 2026-03-30
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT07377487. Inclusion in this directory is not an endorsement.